PHAXIAM Therapeutics S.A.
PHXM.PA
Euronext Paris0.10
EUR
- -
- -
PHAXIAM Therapeutics S.A.
PHXM.PA
(Euronext Paris)
Recent
price
0.10
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- PHAXIAM Therapeutics S.A. (PHXM.PA) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for infectious diseases and neurodegenerative disorders. The company offers a pipeline of product candidates including PHX001, a bacteriophage therapy targeting Escherichia coli and Pseudomonas aeruginosa infections in patients with cystic fibrosis and chronic lung diseases; PHX002, a botulinum toxin-neutralizing antibody for addressing botulism; and other phage-based antimicrobials aimed at combating antibiotic-resistant bacteria. Its services encompass research and development of phage therapies, monoclonal antibodies, and proprietary technologies such as the NexIC platform for rapid phage identification and the AmPhasys system for phage characterization; it also provides contract research services through its specialized platforms. Founded in 2020 through the merger of Pherecydes Pharma and Eradia, PHAXIAM Therapeutics is headquartered in Lyon, France, with operations primarily in Europe. Geographically, the company conducts its activities across France, Switzerland, and other European regions, targeting healthcare providers, hospitals, and patients with severe bacterial infections or neurological conditions. Its business segments include infectious diseases, with emphasis on anti-infective phage therapies for hard-to-treat pathogens, and neurodegenerative diseases through toxin-neutralizing biologics. Key customer types comprise clinicians managing chronic infections, cystic fibrosis centers, and biopharma partners seeking phage technology solutions. In recent developments, PHAXIAM Therapeutics completed a strategic merger in late 2023 to consolidate its phage expertise under a unified brand, enhancing its R&D capabilities. The company announced positive interim data from its PHX001 Phase 1/2 trial in 2024, advancing toward late-stage development for lung infection treatments. Additionally, it secured a research collaboration with a major European biotech firm in early 2025 for co-developing next-generation phage cocktails against multidrug-resistant bacteria, alongside a €10 million funding round to support pipeline expansion.